stockportfolio.pro
Stocks / ADPT vs PRVA
ADPT vs PRVA
Adaptive Biotechnologies Corporation and Privia Health Group, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Adaptive Biotechnologies Corporation (ADPT) | Privia Health Group, Inc. (PRVA) | |
|---|---|---|
| Market cap | $3.0B | $2.9B |
| Revenue (latest FY) | $276.98M | $2.12B |
| Net income (latest FY) | $-59.50M | $22.92M |
| Revenue growth (5y CAGR) | 23.0% | 21.0% |
| Net margin | -21.5% | 1.1% |
| Return on equity | -27.2% | 3.1% |
| P/E ratio | — | 134.0 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 5 |
| Positive free cash flow | No | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ADPT — free Open PRVA — freeFrequently asked questions
Which is bigger, ADPT or PRVA?
Adaptive Biotechnologies Corporation is larger by market capitalization — $3.0B versus $2.9B.
Which grows faster, ADPT or PRVA?
Over the last five fiscal years, Adaptive Biotechnologies Corporation grew revenue faster — 23.0%/yr versus 21.0%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.